Rheumatoid arthritis drugs are used to reduce or prevent joint damage associated with inflammatory conditions of the joints. The short-term goals of rheumatoid arthritis drugs are to reduce joint pain, swelling, and improve joint functions. The long-term goal is to slow or stop the rheumatoid arthritis disease process, majorly joint damage. Rheumatoid arthritis drugs are administered through oral, subcutaneous, and intravenous routes. For the purpose of analysis, the reports segments the global rheumatoid arthritis drugs market into drug class, route of administration, sales channel, and region. In addition, it presents the estimations and forecast of the market. The study estimates the revenue generated from the sale of rheumatic arthritis drugs. The valuations comprise revenue generated from rheumatic arthritis drugs such as disease-modifying antirheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, uric acid drugs, and others. However, it excludes the rheumatic arthritis drugs service revenue. Furthermore, the report excludes revenue generated from post-sale services of rheumatic arthritis drugs.

CHAPTER 1: INTRODUCTION 

CHAPTER 2: EXECUTIVE SUMMARY 

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS

CHAPTER 5: RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION

CHAPTER 6: RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL 

CHAPTER 7: RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION

CHAPTER 8: COMPANY PROFILES